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http://dx.dClofarabine Combined with Busulfan Provides
Excellent Disease Control in Adult Patients with Acute
Lymphoblastic Leukemia Undergoing Allogeneic
Hematopoietic Stem Cell Transplantation
Partow Kebriaei,1 Roland Basset,2 C. Ledesma,1 S. Ciurea,1 S. Parmar,1 E. J. Shpall,1
C. Hosing,1 Issa Khouri,1 M. Qazilbash,1 U. Popat,1 A. Alousi,1 Y. Nieto,1 R. B. Jones,1
M. de Lima,1 R. E. Champlin,1 Borje S. Andersson1We investigated the safety and early disease control data for i.v. busulfan (Bu) in combination with clofarabine
(Clo) in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplan-
tation (SCT). Fifty-one patients (median age, 36 years; range, 20-64 years) received a matched sibling
(n 5 24), syngeneic (n 5 2), or matched unrelated donor transplant (n 5 25) for acute lymphoblastic leu-
kemia in first complete remission (n 5 30), second complete remission (n 5 13), or active disease
(n 5 8). More than one-half of the patients had a high-risk cytogenetic profile, as defined by the presence
of t(9;22) (n 5 17), t(4;11) (n 5 3), or complex cytogenetics (n 5 7). Clo 40 mg/m2 was given once daily,
with each dose followed by pharmacokinetically dosed Bu infused over 3 hours daily for 4 days, followed
by hematopoietic SCT 2 days later. The Bu dose was based on drug clearance, as determined by the patient’s
response to a 32-mg/m2 Bu test dose given 48 hours before the high-dose regimen. The target daily area un-
der the receiver-operating characteristic curve was 5500 mM/min for patients age\60 years and 4000 mM/
min for those age$60 years. The regimenwas well tolerated, with a 100-day nonrelapse mortality rate of 6%.
With a median follow-up of 14 months among surviving patients (range, 6-28 months), the 1-year overall
survival, disease-free survival, and nonrelapse mortality rates were 67% (95% confidence interval [CI],
55%-83%), 54% (95% CI, 41%-71%), and 32% (95% CI, 16%-45%), respectively. For patients undergoing
SCT in first remission, these respective rates were 74%, 64%, and 25%. Our data indicate that the combina-
tion of Clo and Bu provides effective disease control while maintaining a favorable safety profile.
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Allogeneic hematopoietic stem cell transplantation
(SCT) is an effective, potentially curative treatment
option for adults with acute lymphoblastic leukemia
(ALL), but may be associated with significant
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oi.org/10.1016/j.bbmt.2012.06.01020%-45% reported for patients receiving a standard
total body irradiation (TBI)-based myeloablative pre-
parative regimen [1-3]. Reduced-intensity condition-
ing regimens have been associated with reduced
acuteNRM, but with an increased risk of relapse, espe-
cially in patients beyond first complete remission
(CR1) [4-6]. In an attempt to limit the toxicity
associated with TBI-based myeloablative regimens,
we replaced radiation with a chemotherapy-only, dou-
ble-alkylator regimen consisting of i.v. pharmacoki-
netically (PK) dosed busulfan (Bu) and melphalan
(Mel) [7]. We found disease control comparable to
that with radiation-based regimens, with reduced
acute regimen-related toxicity; however, long-term
NRM, related primarily to graft-versus-host disease
(GVHD), remained substantial (55% at 2 years for pa-
tients age .40 years) [7].
Encouraged by reports of a high level of safety and
antileukemic activity achieved with the myeloablative1819
1820 Biol Blood Marrow Transplant 18:1819-1826, 2012P. Kebriaei et al.reduced-toxicity combinations of a nucleoside analog
and i.v. Bu in acute myelogenous leukemia/myelodys-
plastic syndrome [8-10] and more recently in ALL
[11,12], we hypothesized that replacing melphalan
with a nucleoside analog might reduce toxicity while
still providing good disease control in lymphoid
leukemia. Santarone et al. [12] recently reported en-
couraging results in patients with ALL treated with
PK-guided i.v. Bu and fludarabine (Flu), with an over-
all survival (OS) of 63% at 2 years for patients under-
going SCT in CR1. Importantly, long-termNRMwas
only 18% at 2 years.
Clofarabine (Clo) is a second-generation purine
nucleoside analog that is resistant to deamination
and acts as an inhibitor of DNA polymerase and cellu-
lar ribonucleotide reductase. Clinical studies of Flu
and cytosine arabinoside have shown that patients re-
sistant to these agents are still sensitive to Clo [13]. Im-
portantly, in pediatric patients with refractory ALL,
the overall response rate is 20%-30% to monotherapy
with Clo [14] and 60%-70% to combination therapy
including Clo [15]. Clo also has demonstrated antileu-
kemia activity in adults with ALL [16] and acute mye-
logenous leukemia [17]. Given these considerations,
we evaluated the combination of Clo and PK-dosed
Bu as a novel reduced-toxicity regimen with enhanced
antileukemic activity against ALL.PATIENTS AND METHODS
Patient Eligibility
This prospective, phase II single-arm study inves-
tigated the combination of Bu andClo in adult patients
with ALL. Enrollment began in October 2009, and
here we report the outcomes for adult patients treated
consecutively through October 2011. Patients were
between 18 and 65 years of age and underwent alloge-
neic SCT with an available HLA-matched related do-
nor or unrelated donor matched at least at HLA-A, -B,
-C, and -DRB1. Additional eligibility criteria included
creatinine clearance $60 mL/min, alanine amino-
transferase #3 times the upper limit of normal, a Zu-
brod performance status of 0 or 1, no evidence of
uncontrolled infection, and negative serology for hep-
atitis B, hepatitis C, and HIV. Patients were required
to have adequate cardiac function, as demonstrated
by a left ventricular ejection fraction $40%, and
good lung function, as demonstrated by forced expira-
tory volume in 1 second, forced vital capacity, and dif-
fusing capacity of lung for CO2 corrected for
hemoglobin of .50% of predicted. Patients with
active central nervous system (CNS) involvement
were excluded.
Patients received restaging studies with bone mar-
row biopsy within 30 days before study entry, and sub-
sequently at 1 month, 3 months, and 6 months afterSCT, then every 6 months for 3 years, and annually
thereafter, as feasible.
Preparative Regimen
The SCT conditioning regimen consisted of Clo
40 mg/m2 infused over 1 hour, followed by PK-dosed
Bu infused over 3 hours once daily for 4 days, then
SCT 2 days later. The therapeutic dose was based on
the drug clearance rate, as determined by PK testing
using a 32-mg/m2 test dose of Bu infused i.v. over 45
minutes approximately 48 hours before the first thera-
peutic Bu dose. The therapeutic i.v. Bu dose targeted
an average daily area under the receiver-operating
characteristic curve (AUC) of 5500 mM/min for pa-
tients age \60 years and 4000 mM/min for patients
age $60 years. If necessary, a second Bu dose adjust-
ment was made after the first therapeutic dose analysis,
in an effort to keep the total course AUC at 22,000 mM/
min or 16,000 mM/min, depending on age group.
Collection of blood and methods for PK analyses
were performed as reported previously [18-20].
Donors
All donors were HLA-A, -B, -C, and -DRB1 com-
patible with recipients. HLA typing for class I antigens
was performed using standard serologic or low-
resolution molecular techniques, followed by confir-
matory typing with high-resolution molecular typing
of class I and II antigens by PCR for sibling donors
and all unrelated donors.
Peripheral blood stem cells were obtained from do-
nors using standard mobilization protocols and aphere-
sis techniques, with a target progenitor cell dose of
4  106 CD341 cells/kg and a minimal acceptable
dose of 2  106 CD341 cells/kg. Bone marrow was
used if peripheral blood was not available. Stem cells
fromall related donorswere collected atM.D.Anderson
Cancer Center. Peripheral blood progenitor cells or
bone marrow harvests from unrelated donors were ob-
tained through the National Marrow Donor Program.
Supportive Care
Phenytoin 600 mg was administered orally during
and 1 day after completion of i.v. Bu therapy, starting
the evening before the first dose [21]. GVHD prophy-
laxis consisted of a combination of methotrexate and
tacrolimus, with methotrexate 5 mg/m2 i.v. given on
days 11, 13, 16, and 111 and tacrolimus adminis-
tered at a dose to maintain levels between 5 and 15
ng/mL and tapered at the discretion of the treating
physician. Patients who received unrelated donor
products also received rabbit antithymocyte globulin
for a total of 4 mg/kg infused over 3 days starting 3
days before SCT. Patients who developed grade II or
higher acute GVHD received i.v. methylprednisolone
at a dosage of at least 0.5 mg/kg every 6 hours and, if
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GVHD. Institutional transplantation guidelines for
antimicrobial, antifungal, and antiviral prophylaxis
were followed as described previously [22]. Patients
with a previous history of CNS involvement received
posttransplantation intrathecal prophylaxis as feasible.
Finally, patients whowere positive for the Philadelphia
chromosome (Ph) and were in molecular remission af-
ter SCT were started on maintenance therapy with ty-
rosine kinase inhibitor (TKI) on normalization of
blood counts, to continue for 1 year post-SCT. Pa-
tients in continued molecular remission at 1 year after
SCT stopped TKI, but those with persistent minimal
residual disease (MRD) remained on treatment.Table 1. Patient Characteristics at Diagnosis (n 5 51)
Characteristic Value
Age, years, median (range) 36 (20-64)
Age >59 years, n 5
Sex, male/female, n 27/24
Disease lineage, n (%)
B lineage 45 (88)
T lineage 6 (12)
WBC count at diagnosis, n (%)
<30,000/mL 25 (49)
30,000-100,000/mL 7 (14)
>100,000/mL 10 (20)
Unknown 9 (17)
Cytogenetics at diagnosis, n (%)
Diploid 11 (22)
Other 7 (14)
9;22 17 (33)
4;11 3 (6)
Complex 7 (14)
Unknown 6 (11)
Time to achieve CR, n (%)
Within 4 weeks 25 (49)
>4 weeks 23 (45)
Unknown 3 (6)
Disease status at SCT, n (%)
CR1 30 (59)
MRD present 6
CR2 13 (25)
MRD present 8
Not in remission 8 (16)
Lines of chemotherapy pre-SCT, median (range) 1 (1-5)
Time to SCT, months, median (range) 8 (2-115)Definitions and Clinical Outcome Variables
Disease stage at SCTwas defined using established
criteria based on bone marrow morphology. Criteria
for CR included normal cytogenetics, absence of cir-
culating blasts, \5% marrow blasts, and platelet
count $100  109/L. Response was documented as
the best response occurring after 30 days post-SCT.
Standard morphologic criteria were used to diagnose
recurrent disease. Molecular response measured by
quantitative PCR analysis for BCR-ABL rearrange-
ment was obtained when possible. Multiparameter
flow cytometry was used to assess for MRD. MRD
and PCR analyses were not used to assign disease stage
or document relapse. Hematologic recovery was de-
fined as the date that the patient had an absolute neu-
trophil count $0.5  109/L for 3 consecutive days.
Platelet recovery was defined as the first of 7 consecu-
tive days with a platelet count $20  109/L without
transfusion support. Failure to engraft by day 130
was considered primary engraftment failure. Hemato-
poietic chimerism was evaluated in bone marrow (us-
ing unsorted cells) or peripheral blood (with myeloid
and T lineage cell sorting) by restriction fragment
length polymorphism using PCR methods to deter-
mine donor engraftment. Mixed chimerism was de-
fined as the presence of any detectable ($1%)
recipient DNA in addition to donor-derived DNA in
myeloid or T lineage cells.
OS was estimated from the time of SCT until
death from any cause, and patients still alive at last
follow-up were considered censored. Disease-free sur-
vival (DFS) was estimated from the time of SCT up to
the date of relapse or death from any cause. Patients
alive and disease-free at last follow-up were considered
censored. NRM was defined as death from any cause
other than disease progression or relapse. The diagno-
sis of GVHD was confirmed by biopsy when feasible,
but was ultimately determined by clinical presentation.
Acute GVHD was clinically graded as 0-IV based on
standard criteria [23]; chronic GVHD was classified
as none, limited, or extensive [24].Statistical Methods
This is an early report of the first 51 consecutively
treated patients; the trial continues to accrue. The pri-
mary outcomes for this single-arm trial are safety and
OS. Bayesian early-stopping rules based on the ob-
served rates of these 2 outcomes compared with histor-
ical data were implemented [25]. The Kaplan-Meier
estimator [26] was used to estimate the distribution
of OS and DFS times, and distributions were com-
pared using the log-rank test. Descriptive statistics
were used to summarize patient demographic data.
The cumulative incidence of GVHD and relapse
were calculated with death as a competing risk.RESULTS
Patient and Treatment Characteristics
Patient demographic data and baseline disease
characteristics are presented in Table 1. A total of 51
patients, with a median age of 36 years (range, 20-64
years, with 5 patients older than 59 years), were evalu-
ated on this study. The median time from diagnosis to
SCTwas 8 months (range, 2-115 months). The major-
ity of patients had high-risk features at diagnosis, in-
cluding 34% (n 5 17) with an elevated WBC count
at diagnosis, 33% (n 5 17) with the Ph chromosome,
and 45% (n 5 23) taking longer than 4 weeks to
achieve CR1. At the time of SCT, 59% of patients
1822 Biol Blood Marrow Transplant 18:1819-1826, 2012P. Kebriaei et al.(n5 30) were in CR1, including 6 patients with persis-
tent MRD; 25% (n 5 13) were in CR2, including 8
with persistent MRD; and 16% (n 5 8) had more ad-
vanced disease. One patient with T lineage ALL had
active extramedullary disease at the time of SCT. At
the time of diagnosis, 4 patients with T lineage ALL
presented with mediastinal lymphadenopathy, and 4
patients with B lineage ALL had CNS involvement
(n 5 3) or inguinal lymphadenopathy (n 5 1).
Six patients with Ph1 ALL were started on TKI
maintenance therapy at a median of 2 months (range,
1-4 months) after SCT. Five patients received dasati-
nib, at a median dose of 100 mg, and 1 patient received
imatinib. Two patients were started on TKI after re-
lapse, 3 patients declined maintenance therapy, and
the remaining 6 patients did not exhibit adequate re-
covery for initiation of maintenance therapy, owing
to infection or GVHD. All of the Ph1 patients re-
ceived either imatinib or dasatinib with their chemo-
therapy regimen before being referred for SCT.
Graft Content and Engraftment
Stem cell graft characteristics and hematopoietic
recovery data are summarized in Table 2. Approxi-
mately one-half of the patients received a matched re-
lated donor transplant (47%) and one-half received
a matched unrelated donor transplant (49%). Two pa-
tients received a syngeneic SCT. The source of stem
cells was peripheral blood for the majority of patients.
The median total nucleated cell, CD341 cell, and
CD31 cell counts were 6  108/kg (range, 1-
17  108/kg), 5  106/kg (range, 1-13  106/kg), and
166  106/kg (range, 9-330  106/kg), respectively.
The median times to neutrophil and platelet recovery
were 11 days (range, 10-42 days) and 14 days (range, 8-
123 days). We found 100% donor chimerism, assessed
in both the T lineage and myeloid cells, in 49% of the
patients (n 5 23) by day 30 and in 81% of the patients
(n 5 38) by day 100.Table 2. Graft Characteristics at SCT and Hematopoietic
Recovery
Characteristic Value
Donor type, n (%)
Syngeneic 2 (4)
Matched related 24 (47)
Matched unrelated 25 (49)
Stem cell source, n (%)
Bone marrow 16 (15)
Peripheral blood 35 (85)
Graft composition, median (range)
Total nucleated cells 6  108/kg (1-17  108/kg)
CD34+ cells 5  106/kg (1-13  106/kg)
CD3+ cells 166  106/kg (9-330  106/kg)
Time to absolute neutrophil
count recovery, days, median (range)
11 (10-42)
Time to platelet recovery, days,
median (range)*
14 (8-123)
*Four patients did not experience platelet recovery.Two patients experienced early death before day
30 post-SCT due to infection and ensuing end-organ
failure. Another 2 patients received a syngeneic trans-
plant, leaving 47 patients evaluable for chimerism as-
sessment. All patients achieved 100% chimerism in
the myeloid component, but 6 patients retained mixed
chimerism in the T lineage, and 3 patients eventually
relapsed. Of note, among the 5 patients age$60 years,
who received reduced-dose Bu, 4 attained full donor
chimerism at median of 35 days. The patient who
underwent SCT in CR2 but with persistent MRD
remained a mixed chimera, with eventual disease
progression.Response, Relapse, and DFS
Among the 49 patients evaluable for response, 48
maintained or achieved CR. Specifically, 13 patients
with MRD cleared their MRD, and the 6 patients
with marrow CR achieved complete CR with normal-
ization of counts after SCT.
Twelve patients relapsed, at a median of 4.1
months (range, 1.9-21.3 months) after SCT. The esti-
mated relapse rate was 16% at 1 year and 37% at 2
years in patients undergoing SCT in CR1 versus
37% and 46%, respectively, in those undergoing
SCT in more advanced disease. One patient with T
lineage ALL had active disease in the form of persis-
tent abdominal lymphadenopathy at the time of
SCT, and progressed with increasing lymphadenopa-
thy after SCT. Two patients experienced isolated
CNS relapse, 1 of whom had a previous history of
CNS involvement, and 1 patient had an isolated re-
lapse to the CNS dura without positive cerebrospinal
fluid cytology.
DFS was estimated as 54% (95% confidence inter-
val [CI], 41%-71%) at 1 year and 35% (95% CI, 18%-
68%) at 2 years. DFS was significantly better in
patients undergoing SCT in CR1 than in those under-
going SCT with more advanced disease (P 5 .01)
(Figure 1). Estimated 1-yearDFSwas 64% for patients
in CR1, 44% for patients in CR2, and 32% in the latter
group of patients (Figure 1).OS
At the time of this report, 33 patients were alive, at
a median follow-up of 14 months (range, 6-28
months), with and estimated 1-year OS of 67% (95%
CI, 55%-83%) and 2-year OS of 50% (95% CI,
34%-75%). Survival was better in patients in CR1
compared with those with more advanced disease
(Figure 2), although the difference was not statistically
significant (P5 .11). Estimated survival at 1 year and 2
years was 74% for patients undergoing SCT in CR1
compared with 68% and 27%, respectively, in those
undergoing SCT in CR2. Follow-up for patients
Figure 1. DFS by disease stage at time of SCT.
Table 3. Regimen-Related Toxicity in 51 Patients
Toxicity Grade I Grade II Grade III Grade IV
Liver
Bilirubin elevation 2 (4) 12 (24) 2 (4) 0 (0)
Alanine transaminase elevation 15 (29) 7 (14) 13 (25) 0 (0)
Alkaline phosphatase elevation 9 (18) 1 (2)
Gastrointestinal tract
Diarrhea 18 (35) 7 (14) 3 (6) 0 (0)
Nausea 19 (37) 30 (59) 1 (2) 0 (0)
Mucositis 0 (0) 35 (69) 9 (18) 0 (0)
Urinary tract/kidney
Creatinine elevation 1 (2) 0 (0) 1 (2) 0 (0)
Skin
Rash 9 (18) 4 (8) 1 (2) 1 (2)
Neurologic
Dizziness 1 (2) 0 (0) 0 (0) 0 (0)
Headache 2 (4) 3 (6) 0 (0) 0 (0)
Pulmonary/pleural
Pleural effusion 1 (2) 1 (2) 0 (0) 0 (0)
Cardiovascular
Hypertension 2 (4) 1 (2) 0 (0) 0 (0)
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years, with an estimated 1-year OS of 44% (Figure 2).Toxicity, NRM, and GVHD
Regimen-related toxicity assessed by the National
Cancer Institute’s Common Terminology Criteria for
Adverse Events version 3 are detailed in Table 3. No
lethal regimen-related toxicity occurred. The most
commonly observed toxicities involved the gastroin-
testinal tract, including mild (grade I or II) nausea
(98%) and/or diarrhea (49%) and grade II mucositis
(69%). Reversible elevations in liver enzymes were
commonly seen, especially in alanine transaminase
(67%), but there was no case of veno-occlusive disease
(VOD). Approximately one-third of patients devel-
oped a skin rash, mostly grade I or II (n 5 13), and 2
patients developed grade III or IV hand-foot syn-
drome, which was self-limited. One patient developed
renal dysfunction requiring hemodialysis 18 days after
completing his preparative regimen, in the context of
receiving multiple nephrotoxic medications. NRMFigure 2. OS by disease stage at time of SCT.estimates were 6% (95% CI, 0%-12%) at 100 days,
32% (95% CI, 16%-45%) at 1 year, and 43% (95%
CI, 20%-60%) at 2 years (Figure 3A), with higher rates
of late NRM in patients undergoing SCT with more
advanced disease (Figure 3B). No regimen-related
deaths occurred within the first 100 days of transplan-
tation in the 5 patients age$60 years; however, NRM
was significantly higher in patients age .40 years
(P 5 .0006) (Figure 3C). There were 18 deaths, due
to infection (n 5 4), myocardial infarction (n 5 1),
acute GVHD (n 5 3), chronic GVHD (n 5 4), and
relapse (n 5 6).
The cumulative incidence rates of grade II-IV and
grade III-IV acute GVHD were 38% (95% CI, 24%-
51%) and 12% (95%CI, 3%-21%), respectively; there
was no statistically significant difference between pa-
tients receiving grafts from matched related donors
and those receiving grafts from unrelated donors.
The cumulative incidence of chronic GVHD was
15% (95% CI, 3%-28%), with 7% (95% CI, 0%-
17%) experiencing extensive GVHD. Again, no differ-
ences were noted among allotypes (Table 4). Finally,
no differences in GVHD rates were noted with respect
to stem cell source.DISCUSSION
The development of a nucleoside analog i.v. Bu-
based preparative regimen is especially appealing for
patients with ALL, which has a bimodal incidence. In
young patients, inwhomALL ismost common, the op-
tion to avoid radiation is particularly important, given
the long-term toxicities associated with TBI, including
impaired growth and cognitive function [27,28],
increased incidence without plateau in secondary
malignancies [29,30], and increased incidence of the
cardiometabolic trait, leading to diabetes and
Figure 3. NRM for the total study group (A), by disease stage (B), and
by age (C).
Table 4. Cumulative Incidence of Acute and Chronic GVHD
Acute GVHD, n (%)
Grade II-IV 19 (38)
Grade III-IV 5 (12)
Chronic GVHD, n (%)
Limited and/or extensive 8 (15)
Extensive 4 (7)
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[31,32]. A large proportion of patients with ALL are
age .50 years. Myeloablative TBI-containing prepar-
ative regimens are associated with substantial toxicity
in this age group, and an effective reduced-toxicity
transplant preparative regimen is needed. This is the
first report of combination Clo-Bu therapy in patients
with ALL. The projected 2-year OS rate of 74% inCR1 patients compares favorably with reported sur-
vival rates of approximately 45%-55% in adult patients
treated with ‘‘standard’’ TBI-based regimens [2,33,34].
The complete response rates of 98%, and the
elimination of MRD in 100% of patients who had
residual disease detectable by flow cytometry at time
of SCT, attest to the antileukemic activity of this
combination.
The new regimen was relatively well tolerated,
with a 100-day mortality rate of 6%. Transient trans-
aminitis was common, as also reported by Magenau
et al. [35]. However, no patients developed VOD
with this regimen, even though 5 patients with refrac-
tory disease received inotuzumab ozogamicin, a CD22
monoclonal antibody conjugated to the toxin cale-
cheamicin before SCT. Inotuzumab was demonstrated
to have hepatic toxicity, including VOD, in a phase 2
study of patients with refractory ALL [36]. The rates
of acute GVHD (38% grade II-IV and 12% grade
III-IV; Table 4) are comparable to rates reported for
from radiation-based [33] and non–radiation-based
regimens [12] and is substantially lower than the rate
seen in our previous trial of Bu-melphalan combina-
tion therapy [7]. NRM at 2 years was 43%
(Figure 3A), and was significantly higher in patients
age .40 years (Figure 3C), largely accounted for by
GVHD. Thus, reducing the rate of GVHD, especially
in older patients, may significantly reduce the risk of
late NRM, given that 7 (14%) of our patients died of
GVHD-related complications.
The administration of PK-guided busulfan allows
for accurate dose delivery within a tighter range of sys-
temic drug exposure [7]. Our group [8,21,37] and
others [10-12] have identified an optimal daily Bu
dose AUC within a window of 3800 mM/min (when
used with low-dose TBI) to 6080 mM/min when com-
bined only with a nucleoside analog. Thus, in an effort
to minimize toxicity, we targeted a median daily dose
AUC of 5500 mMol/min for our patients age\60 years
formaximumdisease control and 4000 mM/min for our
patients age $60 years. We have shown reliable en-
graftment with this lower-dose Bu-Flu combination
regimen in patients with myeloproliferative disorders
undergoing allogeneic SCT [38]. There were no
treatment-related deaths in the 5 patients age $60
years treated with this reduced-dose regimen. Four of
these 5 patients achieved full donor chimerism after
conditioning with reduced-dose Clo-Bu; 1 patient
with low-level disease at the time of SCT achieved
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study of more patients is needed to determine the
NRM profile and antileukemia activity of the
reduced-dose Clo-Bu regimen.
Despite a high rate of CR after SCT, relapse re-
mains the major cause of treatment failure, particularly
in patients with active disease, who had a 2-year DFS
of 32% (Figure 1). Preliminary data suggest that the
addition of a biological modifier, such as a histone de-
acetylase inhibitor [39] or a DNA methyltransferase
inhibitor to ‘‘sensitize’’ the leukemia to cytotoxic che-
motherapy [40], add synergy to cytotoxic chemother-
apy combinations in lymphoma cell lines. The
incorporation of such agents into the current Clo-Bu
combination would be expected to have nonoverlap-
ping toxicities and is especially appealing as we con-
tinue to try to increase efficacy yet limit NRM.
In conclusion, the Clo-Bu preparative regimen
produces excellent disease control in high-risk patients
with ALL, while maintaining a favorable toxicity pro-
file. This regimen provides a potential platform to
study novel approaches to improving disease control.
Randomized studies are warranted to compare this
regimen with other commonly used preparative regi-
mens for treatment of ALL.ACKNOWLEDGMENT
Financial disclosure: Borje Andersson is a consultant
to Otsuka America Pharmaceuticals, Inc. The authors
have no conflicts of interest to disclose.REFERENCES
1. Sutton L, Kuentz M, Cordonnier C, et al. Allogeneic bone mar-
row transplantation for adult acute lymphoblastic leukemia in
first complete remission: factors predictive of transplant-
related mortality and influence of total body irradiation modal-
ities. Bone Marrow Transplant. 1993;12:583-589.
2. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with
standard-risk acute lymphoblastic leukemia, the greatest benefit
is achieved from a matched sibling allogeneic transplantation in
first complete remission, and an autologous transplantation is
less effective than conventional consolidation/maintenance che-
motherapy in all patients: final results of the International ALL
Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:
1827-1833.
3. Oliansky DM, Larson RA, Weisdorf D, et al. The role of cyto-
toxic therapy with hematopoietic stem cell transplantation in the
treatment of adult acute lymphoblastic leukemia: update of the
2006 evidence-based review. Biol Blood Marrow Transplant.
2012;18:18-36.
4. MohtyM, LabopinM, Tabrizzi R, et al. Reduced-intensity con-
ditioning allogeneic stem cell transplantation for adult patients
with acute lymphoblastic leukemia: a retrospective study from
the European Group for Blood and Marrow Transplantation.
Haematologica. 2008;93:303-306.
5. Hamaki T, KamiM, Kanda Y, et al. Reduced-intensity stem-cell
transplantation for adult acute lymphoblastic leukemia: a retro-
spective study of 33 patients. Bone Marrow Transplant. 2005;35:
549-556.6. Martino R, Giralt S, Caballero MD, et al. Allogeneic hemato-
poietic stem cell transplantation with reduced-intensity condi-
tioning in acute lymphoblastic leukemia: a feasibility study.
Haematologica. 2003;88:555-560.
7. Kebriaei P, MaddenT,Wang X, Thall PF, Ledesma C, de Lima
M, Shpall EJ, Hosing C, QazilbashM, Popat U, Alousi A, Nieto
Y, Champlin RE, Jones RB, Andersson BS.Intravenous BU plus
Mel: an effective, chemotherapy-only transplant conditioning
regimen in patients with ALL. Bone Marrow Transplant. 2012
Jun 25. doi: 10.1038/bmt.2012.114. [Epub ahead of print]
8. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous
busulfan and fludarabine: clinical and pharmacokinetic results of
a myeloablative, reduced-toxicity conditioning regimen for allo-
geneic stem cell transplantation in AML and MDS. Blood. 2004;
104:857-864.
9. Andersson BS, Valdez BC, de Lima M, et al. Clofarabine 1/-
fludarabine with once daily i.v. busulfan as pretransplant condi-
tioning therapy for advanced myeloid leukemia and MDS. Biol
Blood Marrow Transplant. 2011;17:893-900.
10. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous
busulfan given with fludarabine as conditioning for allogeneic
stem cell transplantation: study of pharmacokinetics and early
clinical outcomes. Biol Blood Marrow Transplant. 2002;8:
468-476.
11. Russell JA, Savoie ML, Balogh A, et al. Allogeneic transplanta-
tion for adult acute leukemia in first and second remission
with a novel regimen incorporating daily intravenous busulfan,
fludarabine, 400 cGy total body irradiation, and thymoglobulin.
Biol Blood Marrow Transplant. 2007;13:814-821.
12. Santarone S, Pidala J, Di Nicola M, et al. Fludarabine and
pharmacokinetic-targeted busulfan before allografting for adults
with acute lymphoid leukemia. Biol Blood Marrow Transplant.
2011;17:1505-1511.
13. ParkerWB, Shaddix SC, ChangCH, et al. Effects of 2-chloro-9-
(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562
cellular metabolism and the inhibition of human ribonucleotide
reductase and DNA polymerases by its 50-triphosphate. Cancer
Res. 1991;51:2386-2394.
14. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofara-
bine in pediatric patients with refractory or relapsed acute lym-
phoblastic leukemia. J Clin Oncol. 2006;24:1917-1923.
15. O’Connor D, Sibson K, Caswell M, et al. Early UK experience
in the use of clofarabine in the treatment of relapsed and refrac-
tory paediatric acute lymphoblastic leukaemia. Br J Haematol.
2011;154:482-485.
16. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and
pharmacologic study of clofarabine in patients with refractory
or relapsed acute leukemia. Blood. 2003;102:2379-2386.
17. Faderl S, Gandhi V, O’Brien S, et al. Results of a phase 1-2 study
of clofarabine in combination with cytarabine (ara-C) in re-
lapsed and refractory acute leukemias. Blood. 2005;105:940-947.
18. Kebriaei P, Madden T, Kazerooni R, et al. Intravenous busulfan
plus melphalan is a highly effective, well-tolerated preparative
regimen for autologous stem cell transplantation in patients
with advanced lymphoid malignancies. Biol Blood Marrow Trans-
plant. 2011;17:412-420.
19. Madden T, de Lima M, Thapar N, et al. Pharmacokinetics of
once-daily IV busulfan as part of pretransplantation preparative
regimens: a comparison with an every 6-hour dosing schedule.
Biol Blood Marrow Transplant. 2007;13:56-64.
20. D’Argenio,D.Z., A. Schumitzky andX.Wang. ADAPT5User’s
Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis
Software. Biomedical Simulations Resource, Los Angeles, 2009.
21. Andersson BS, Madden T, Tran HT, et al. Acute safety and
pharmacokinetics of intravenous busulfan when used with oral
busulfan and cyclophosphamide as pretransplantation condi-
tioning therapy: a phase I study. Biol Blood Marrow Transplant.
2000;6:548-554.
22. Kebriaei P, Saliba R, Rondon G, et al. Long-term follow-up of
allogeneic hematopoietic stem cell transplantation for patients
with Philadelphia chromosome-positive acute lymphoblastic
1826 Biol Blood Marrow Transplant 18:1819-1826, 2012P. Kebriaei et al.leukemia: impact of tyrosine kinase inhibitors on treatment out-
comes. Biol Blood Marrow Transplant. 2012;16:584-592.
23. Przepiorka D,Weisdorf D, Martin P, et al. 1994 consensus con-
ference on acuteGVHDgrading. BoneMarrow Transplant. 1995;
15:825-828.
24. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-
versus-host disease in 52 patients: adverse natural course and
successful treatment with combination immunosuppression.
Blood. 1981;57:267-276.
25. Thall PF, Wathen JK. Covariate-adjusted adaptive randomiza-
tion in a sarcoma trial with multi-stage treatments. Stat Med.
2005;24:1947-1964.
26. Kaplan EL, Meier P. Non-parametric estimation from incom-
plete observations. J Am Stat Assoc. 1958;53:457-481.
27. Bushhouse S, Ramsay NK, Pescovitz OH, et al. Growth in chil-
dren following irradiation for bone marrow transplantation. Am
J Pediatr Hematol Oncol. 1989;11:134-140.
28. Sanders JE. Seattle Marrow Transplant Team. The impact of
marrow transplant preparative regimens on subsequent growth
and development. Semin Hematol. 1991;28:244-249.
29. Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up
among survivors of childhood acute lymphoblastic leukemia:
a report from the Childhood Cancer Survivor Study. Blood.
2008;111:5515-5523.
30. Meadows AT, FriedmanDL,Neglia JP, et al. Second neoplasms
in survivors of childhood cancer: findings from the Childhood
Cancer Survivor Study cohort. J Clin Oncol. 2009;27:2356-2362.
31. Chow EJ, Simmons JH, Roth CL, et al. Increased cardiometa-
bolic traits in pediatric survivors of acute lymphoblastic leuke-
mia treated with total body irradiation. Biol Blood Marrow
Transplant. 2010;16:1674-1681.
32. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension,
and cardiovascular events in survivors of hematopoietic cell
transplantation: a report from the Bone Marrow Transplanta-
tion Survivor Study. Blood. 2007;109:1765-1772.33. Marks DI, Wang T, Perez WS, et al. The outcome of full-
intensity and reduced-intensity conditioning matched sibling
or unrelated donor transplantation in adults with Philadelphia
chromosome–negative acute lymphoblastic leukemia in first
and second complete remission. Blood. 2010;116:366-374.
34. ThomasX, Boiron JM,Huguet F, et al. Outcome of treatment in
adults with acute lymphoblastic leukemia: analysis of the LALA-
94 trial. J Clin Oncol. 2004;22:4075-4086.
35. Magenau J, Tobai H, Pawarode A, et al. Clofarabine and busul-
fan conditioning facilitates engraftment and provides significant
antitumor activity in nonremission hematologic malignancies.
Blood. 2011;118:4258-4264.
36. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozoga-
micin, an anti-CD22–calecheamicin conjugate, for refractory
and relapsed acute lymphocytic leukaemia: a phase 2 study. Lan-
cet Oncol. 2012;13:403-411.
37. Andersson BS, Thall PF, Madden T, et al. Busulfan systemic
exposure relative to regimen-related toxicity and acute graft-
versus-host disease: defining a therapeutic window for i.v.
BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow
Transplant. 2002;8:477-485.
38. Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G,
Champlin RE, Storb R, Prchal JT, Gooley TA, Deeg HJ. Allo-
geneic haematopoietic cell transplantation for myelofibrosis in
30 patients 60-78 years of age. Br J Haematol. 2011;153:76-82.
http://dx.doi.org/10.1111/j.1365-2141.2011.08582.x. Epub 2011
Feb 17.
39. Valdez BC, Murray D, Nieto Y, et al. Synergistic cytotoxicity of
the DNA alkylating agent busulfan, nucleoside analogs and sub-
eroylanilide hydroxamic acid in lymphoma cell lines. Leuk Lym-
phoma. 2012;53:973-981.
40. Valdez BC, Li Y, Murray D, et al. 5-Aza-20-deoxycytidine sensi-
tizes busulfan-resistant myeloid leukemia cells by regulating
expression of genes involved in cell cycle checkpoint and apopto-
sis. Leukemia Res. 2010;34:364-372.
